Condition (MeSH)
Wasting Syndrome
ClinicalTrials.gov lists 19 trials for Wasting Syndrome or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 19 trials are tagged with Wasting Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Wasting Syndrome trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 2 |
| 2015 | 1 |
| 2011 | 1 |
| 2004 | 1 |
| 2002 | 1 |
| 2000 | 1 |
| 1999 | 1 |
| 1998 | 2 |
| 1997 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 19 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Wasting Syndrome trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Phase 3 | 1 |
| Phase 4 | 2 |
| Not applicable | 5 |
| Observational | 3 |
How many Wasting Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 17 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Wasting Syndrome trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 7 |
| Celgene Corporation | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| Novartis Pharmaceuticals | 2 |
| EMD Serono | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Wasting Syndrome? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| THALIDOMIDE | 2 |
| Oxandrolone | 1 |
| Dronabinol | 1 |
| Testosterone Enanthate | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Megstrol Acetate | 3 |
| Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL | 1 |
| Atazanavir + Ritonavir | 1 |
| Testosteron | 1 |
| Somatropin; Recombinant human growth hormone (r hGH) | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Wasting Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Malignant neoplasm progression | 10 | 1 |
| Blood cortisol abnormal | 9 | 1 |
| Adrenal insufficiency | 7 | 1 |
| Adrenal suppression | 4 | 1 |
| Anaemia | 4 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Wasting Syndrome? (107)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Micronutrient status in children aged 6-59 months with severe wasting and/or nutritional edema: implications for nutritional rehabilitation formulations. | Nutrition reviews | 2025 | Yes |
| Egg supplementation for 24 weeks does not improve linear growth or reduce small intestinal permeability in Sierra Leonean children with moderate wasting: a randomized, blinded, controlled trial. | The American journal of clinical nutrition | 2025 | Yes |
| Analysing concordance between MUAC, MUACZ, and WHZ in diagnosing acute malnutrition among children under five in Somalia. | Journal of global health | 2025 | Yes |
| Assessing the correlates of wasting among children under five and their mothers in the Bay and Hiran regions of Somalia. | Journal of global health | 2025 | Yes |
| Effect of a simplified approach on recovery of children 6-59 months with wasting in Ethiopia: A noninferiority, cluster randomized controlled trial. | Maternal & child nutrition | 2024 | Yes |
Showing 5 of 107 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.